ABCA1 acts as a protective modulator in amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Genetics
• Biomarker Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited diagnostic tools and treatments.
• The lack of reliable biomarkers hinders early detection and therapeutic development for ALS.

Purpose of the Study:

• To develop a diagnostic signature for ALS using an integrative, multiscale approach.
• To identify novel biomarkers and therapeutic targets for ALS, focusing on the role of ATP-binding cassette transporter A1 (ABCA1).

Main Methods:

• Integrative analysis combining epidemiology, whole-blood transcriptomics, machine learning, and Mendelian randomization (MR).
• Development and validation of a nine-gene diagnostic signature for ALS.
• Assessment of ABCA1 expression at transcript and protein levels in patient cohorts and animal models.

Main Results:

• A nine-gene signature demonstrated diagnostic capability with an AUC of 0.75 in external validation.
• ABCA1 was identified as a central feature, with MR analyses suggesting a protective causal effect against ALS risk.
• Serum ABCA1 levels were significantly elevated in an ALS cohort and correlated with metabolic parameters; ABCA1 upregulation was confirmed in patient tissues and ALS models.

Conclusions:

• A validated diagnostic signature for ALS has been established.
• ABCA1 is identified as a compensatory biomarker in ALS, potentially offering neuroprotection and highlighting the link between metabolic adaptation and neurodegeneration.